DBX Putty

Main information

  • Trade name:
  • DBX Putty
  • INN (International Name):
  • Bone
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • DBX Putty
    Australia
  • Language:
  • English

Other information

Status

  • Source:
  • Dept. of Health,Therapeutic Goods Administration - Australia
  • Authorization number:
  • 211454
  • Last update:
  • 09-10-2017

Public Assessment Report

Public Summary

Summary for ARTG Entry:

211454

Musculoskeletal Tissue - DBX Putty - Johnson & Johnson Medical Pty Ltd t/a DePuy Synthes - Paste -

Syringe

ARTG entry for

Biological Included Class 3

Sponsor

Johnson & Johnson Medical Pty Ltd t/a DePuy Synthes

Postal Address

PO Box 134,NORTH RYDE, NSW, 2113

Australia

ARTG Start Date

26/06/2013

Product category

Included Class 3

Status

Active

Approval area

Biologicals

Conditions

Conditions applicable to all included biologicals as specified in section 32EA of the Act.

Products

1. DBX Putty

Product Type

Musculoskeletal Tissue

Effective date

10/05/2017

Therapeutic indication

DBX is indicated for treatment of surgically created osseous defects or osseous defects created from

traumatic injury. DBX can be used as an extender in orthopaedic spine and trauma use with autograft,

allograft and bone marrow aspirate.

Specific Conditions

6) The sponsor must comply with any reporting requirements that are prescribed. For the purpose of this condition the reporting requirements set out in

section 32 DQ of the Act must be complied with, specifically the Sponsor must inform the Secretary in writing, within the periods specified in the

regulations, of: a) information that contradicts information already given by the person under this Act in relation to the biological (including information

given about the quality, safety or efficacy of the biological): b) information that indicates that the use of the biological in accordance with the

recommendations for its use may have an unintended harmful effect and: c) information that indicates that the biological, when used in accordance with

the recommendations for its use, may not be as effective as the application for inclusion of the biological in the Register or information already given by

the person under this Act suggests. Note: Section 32DQ of the Act also provides for penalties where the Sponsor of the goods fails to inform the

Secretary in writing of the matters set out in section 32DQ.

5) The DBX Putty Risk Management Plan (RMP), version AE, dated 06 June 2013, included with submission BIO-2011-BA-00004-3, and any

subsequent revisions, as agreed with the TGA must be implemented in Australia. An obligatory component of the Risk Management Plan applicable to

this therapeutic good is Routine Pharmacovigilance. Routine Pharmacovigilance includes the submission of Periodic Safety Update Reports (PSURs).

The reports must meet the requirements for Periodic Safety Update Reports as described in the European Medicines Agency's Guideline on Good

Pharmacovigilance Practices (GVP) Module VII-Periodic Safety Update Report. Each report must have been prepared within seventy calendar days of

the data lock point for that report, as required by the European Medicines Agency's Guideline for PSUR's covering intervals up to 12 months (including

intervals of exactly 12 months). Unless agreed separately between the supplier who is the recipient of the approval and the TGA, the first report must be

submitted to TGA no later than 15 calendar months after the date of this letter. The subsequent reports must be submitted no less frequently than

annually from the date of the first submitted report until the period covered by such reports is not less than three years from the date of this approval

letter. No fewer than three annual reports are required. The annual submission may be made up of two Periodic Safety Update Reports each covering

six months. If the sponsor wishes, the six monthly reports may be submitted separately as they become available. Another obligatory component of the

Risk Management Plan applicable to the therapeutic good is traceability of the biological material from the point of collection of donor tissue through to

the recipient

4) The actual date of commencement of supply of the therapeutic good must be notified to the Director, Biological Sciences Section of the TGA. Should it

be decided not to proceed to supply the therapeutic good in Australia, notification to this effect must be provided to the Director, Biological Sciences

Section of the TGA. A copy of the notification form has been provided as Attachment 5

3) Promotional material relating to the therapeutic good must comply with the requirements outlined in the Code of Conduct of Medicines Australia,

Edition 17 effective 11 January 2013 (http://medicinesaustralia.com.au/code-of-conduct/)

2) Changes or variations in respect of any information concerning the therapeutic good that would have been relevant to a decision to include the goods

in the ARTG, shall be notified to the Secretary, or the Secretary's delegate appointed for the purposes of section 32ED of the Act. This includes

information on the formulation of the goods or other aspects of their manufacture and the labelling of the goods. The change or variation shall not be

implemented until approved by the Secretary

1) The therapeutic good must be supplied with the Product Insert at Attachment 4. Any proposed changes to the approved text of the PI must be

submitted to, and be approved by, the TGA prior to distribution

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

Public Summary

Page 1 of

Produced at 22.11.2017 at 11:49:42 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information

15-10-2018

Toy Land Company recalls Boom Boom ChemsSlime andPutty

Toy Land Company recalls Boom Boom ChemsSlime andPutty

Health Canada has determined that the slime and putty products do not meet the Canadian toy safety requirements related to boric acid content.

Health Canada

28-8-2018

New recommendations for use of Xofigo for treatment of prostate cancer which has spread to the bones

New recommendations for use of Xofigo for treatment of prostate cancer which has spread to the bones

The EU's Pharmacovigilance Risk Assessment Committee (PRAC) has adopted new recommendations for use of Xofigo for treatment of prostate cancer which has spread to the bones (bone metastases). Xofigo should only be used in symptomatic patients who have had two previous treatments for prostate cancer and who cannot be treated with other medicines.

Danish Medicines Agency

29-6-2018

Wish Bone Salad Dressing Issues Allergy Alert On Undeclared Milk and Egg in 15 oz. Wish-Bone House Italian Salad Dressing

Wish Bone Salad Dressing Issues Allergy Alert On Undeclared Milk and Egg in 15 oz. Wish-Bone House Italian Salad Dressing

Pinnacle Foods Inc. is voluntarily recalling a limited quantity of Wish Bone House Italian Salad Dressing 15 oz. with the health and safety of our consumers as our top priority. The recall was initiated after learning from a retail customer that a limited number of bottles were mislabeled. The product contains milk and egg, known allergens not declared on the bottle. People who have an allergy or severe sensitivity to milk or egg may run the risk of a serious or life-threatening allergic reaction if t...

FDA - U.S. Food and Drug Administration

4-5-2018

 Slime: a very popular toy putty that is not without risk

Slime: a very popular toy putty that is not without risk

ANSES and the DGCCRF are alerting consumers to the risks associated with making and handling "slime". Slime, a sticky and elastic putty for kneading, is currently very popular with children and adolescents. It is commercially available in ready-to-use form or in kits. It can also be made at home, in order to vary its appearance and texture (by adding colour, glitter, etc.). Tutorials on how to make slime have proliferated on the Internet and offer many recipes, based on ingredients such as paper glue and...

France - Agence Nationale du Médicament Vétérinaire

4-5-2018

Slime: a very popular toy putty that is not without risk

Slime: a very popular toy putty that is not without risk

France - Agence Nationale du Médicament Vétérinaire

22-2-2012

Decision on general conditional reimbursement for alendronate-containing medicines

Decision on general conditional reimbursement for alendronate-containing medicines

In cooperation with the Reimbursement Committee, we have decided to grant alendronate-containing medicines general conditional reimbursement from 5 March 2012. Reimbursement is conditional as it is reserved for patients with low-energy hip fractures. For any other patients who are treated with alendronate, the doctor must apply for single reimbursement, and the guiding criteria for single reimbursement remain unchanged for these patients. Alendronate is used for the treatment of osteoporosis (brittle bon...

Danish Medicines Agency

13-8-2018

EU/3/18/2045 (Dystrogen Therapeutics S.A.)

EU/3/18/2045 (Dystrogen Therapeutics S.A.)

EU/3/18/2045 (Active substance: Ex-vivo fused autologous human bone marrow-derived mesenchymal stem cell with allogenic human myoblast) - Orphan designation - Commission Decision (2018)5277 of Mon, 13 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/028/18

Europe -DG Health and Food Safety

2-8-2018

EU/3/18/2044 (medac Gesellschaft fUr klinische SpezialprAparate mbH)

EU/3/18/2044 (medac Gesellschaft fUr klinische SpezialprAparate mbH)

EU/3/18/2044 (Active substance: Allogeneic bone marrow derived mesenchymal stromal cells, ex-vivo expanded) - Orphan designation - Commission Decision (2018)5276 of Thu, 02 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/023/18

Europe -DG Health and Food Safety

29-5-2018

EU/3/18/2026 (Alnylam UK Limited)

EU/3/18/2026 (Alnylam UK Limited)

EU/3/18/2026 (Active substance: Synthetic double-stranded siRNA oligonucleotide targeted against transthyretin mRNA, with six phosphorothioate linkages in the backbone, and nine 2'-fluoro and thirty-five 2'-O-methyl nucleoside residues in the sequence, which is covalently linked via a phosphodiester group to a ligand containing three N-acetylgalactosamine residues) - Orphan designation - Commission Decision (2018)3394 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/019/18

Europe -DG Health and Food Safety